gavreto
roche registration gmbh - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikulært - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiske - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
minimet minigranulat
rotam agrochemical europe limited - metsulfuron-methyl, metsulfuron - minigranulat - 200 g/kg metsulfuron-methyl ; (~ 193 g/kg metsulfuron
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
ergon vanddispergerbart granulat
rotam agrochemical europe limited - thifensulfuron-methyl, thifensulfuron, metsulfuron-methyl, metsulfuron - vanddispergerbart granulat - 682 g/kg thifensulfuron-methyl ; (~ 657 g/kg thifensulfuron ; 68 g/kg metsulfuron-methyl ; (~ 65,5 g/kg metsulfuron
nautius vanddispergerbart granulat
rotam agrochemical europe limited - tribenuron-methyl, tribenuron, thifensulfuron-methyl, thifensulfuron - vanddispergerbart granulat - 150 g/kg tribenuron-methyl ; (~ 145 g/kg tribenuron ; 400 g/kg thifensulfuron-methyl ; (~ 386 g/kg thifensulfuron
savvy minigranulat
rotam agrochemical europe limited - metsulfuron-methyl, metsulfuron - minigranulat - 200 g/kg metsulfuron-methyl ; (~ 193 g/kg metsulfuron